When applied to clinical development, Quality by Design is an approach that focuses effort on prospectively identifying and managing risk to improve clinical trial quality and outcomes. The application of Quality by Design principles is particularly important in rare diseases, where the limited, geographically-dispersed, and often vulnerable patient pool leaves little margin for error. By...
Sponsors of psychiatric clinical trials may face significant challenges in collecting robust, quality data to support the efficacy and safety of investigative compounds. Identifying and mitigating study design-, subject-, and site-related factors that may influence data quality as early as possible in program development can help to drive study success. Ensuring that psychiatric clinical trial...
Central nervous system (CNS) disorders are a diverse group of conditions that include psychiatric, neurological and substance abuse disorders. Unfortunately for patients, treatment options for CNS disorders are often limited (or non-existent). To make matters worse, comparatively few CNS drugs are in the development pipeline. What aspects of CNS disorders contribute to lagging drug development? Read on to...
DURHAM, N.C., October 9, 2016 — Premier Research’s quality assurance chief will chair a session at the Research Quality Association’s 2016 Annual Conference in Brighton, U.K. Nicky Dodsworth, Vice President of Global Quality Assurance, will lead the session taking place Thursday, November 10, starting at 9 a.m. Stream C, Session 1 at the RQA conference...
DURHAM, N.C., OCTOBER 27, 2016 — Medical device and diagnostic companies are conducting more clinical trials than ever, a trend that’s giving rise to new procedures and best practices for studies that differ in many ways from pharmaceutical trials. Register for this webinar focused on the evolution of device clinical research on Wednesday, November 2....
Quality and effective risk management are vital to every clinical trial, and their importance is greater still when working in rare indications. Your patient population is small, vulnerable, and geographically dispersed, so there’s limited data and little opportunity to replicate clinical trial results. It’s as if the phrase “get it right the first time” had...
The challenges of greater regulatory scrutiny, complex logistics, downward cost pressure and increasingly rigorous data requirements are just a few of the reasons biotech and pharmaceutical companies look to outsource clinical trials. In a dynamic healthcare and regulatory environment, outsourcing increases flexibility by streamlining clinical trial management and enabling sponsors to concentrate their resources on...
DURHAM, N.C., April 05, 2016 – New European Union standards governing clinical research have significant implications for future drug trials. Nicky Dodsworth, Vice President, Quality Assurance, Risk & Compliance at Premier Research, will discuss these changes at the 2016 West and Wales Regional Forum on Innovation and Risk, April 21 in Milton Park, Oxfordshire, U.K. In...
PHILADELPHIA, November 20, 2015 — Proposed updates to the International Conference for Harmonization Good Clinical Practice guidelines would be the most significant changes to international clinical research guidance in 20 years. What’s changing, and how will it affect you? Nicky Dodsworth, Vice President for Global Quality Assurance at Premier Research, will discuss proposed revisions to...
PHILADELPHIA, October 21, 2015 — Clinical research must produce consistent, reproducible results to be of real value. But too often, underlying decisions are based on opinions and not on well-defined, objective criteria, complicating things and making objectivity impossible. Nicky Dodsworth, Vice President for Global Quality Assurance at Premier Research, will address this issue at the...